[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
October 25, 1999

The Use of Sublingual NifedipineA Continuing Concern

Arch Intern Med. 1999;159(19):2259-2260. doi:10.1001/archinte.159.19.2259

IN 1995, the Cardiorenal Advisory Committee of the Food and Drug Administration, after a lengthy deliberation, unanimously decided that sublingual nifedipine should not officially be approved for the treatment of hypertensive emergencies. Despite this decision and despite authoritative voices14 warning against this practice, the use of short-acting nifedipine for what was perceived as hypertensive emergencies remained widespread in the United States and all over the globe.

First Page Preview View Large
First page PDF preview
First page PDF preview
×